Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal Takes A Step Forward On Biosimilars

FDA Accepts Filing For Bevacizumab Rival To Avastin, Partnered With Mabxience

Executive Summary

The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.

You may also be interested in...



Amneal Plans ‘Meaningful Additions’ To Its Generics Portfolio

Amneal continues to focus on new generics launches as the company sees its quarterly and half-yearly revenues increase on the back of its new launches and generics portfolio. The US-based company said that it was looking to continue its shift towards complex generics, as it considers eventually building in-house capabilities for biosimilars.

Amneal Adds Another Complex Generic With TobraDex Approval

Amneal has broadened its complex generics portfolio by gaining FDA approval for its generic version of ophthalmic combination medicine TobraDex.

Keeping Track: StrataGraft Continues US FDA’s Biologic Center Approvals Streak; Another CRL For Avenue’s Tramadol IV

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel